Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...

Regulatory B cells (Breg) have emerged as pivotal modulators of the immune system, mediating immune tolerance and preventing excessive inflammatory responses. These specialised B cells exert their ...

Engineered bacteria reprogram tumor macrophages and direct copper into cancer cells, triggering cell death and systemic immunity without damaging healthy tissue. (Nanowerk Spotlight) Tumors do not ...

Chronic diabetic ulcers represent one of the most challenging complications in modern healthcare, affecting over 131 million people worldwide and generating approximately $755 billion in annual ...

Engineered immune cell therapies offer the promise of more tailored interventions than traditional systemic checkpoint blockades, but so far remain ineffective across the majority of clinical settings ...

Sepsis remains a major challenge in modern medicine, claiming millions of lives each year. For decades, clinical management has largely focused on suppressing excessive inflammation. Yet many patients ...

Northwestern Medicine scientists have discovered how calcium signaling channels in microglia—the primary immune cells of the ...

Cellular senescence, a state characterized by stable cell cycle arrest, has emerged as a critical process in maintaining tissue homeostasis by limiting the ...

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 10 Must-Watch Stocks Right Now. ImmunityBio surged by 7.29 percent on Friday to ...